Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionFSCC - Federated Hermes MDT Small Cap Core ETF
Latest Disclosed Ownership26,574 shares
Latest Disclosed Value $ 613,327
FSCC - Federated Hermes MDT Small Cap Core ETF reports 130.26% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On April 23, 2026 - FSCC - Federated Hermes MDT Small Cap Core ETF filed a NPORT-P form disclosing ownership of 26,574 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $613,328 USD as of February 28, 2026. The entity filed a previous NPORT-P on January 23, 2026 disclosing 11,541 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 130.26% during the quarter. The current value of the position is $836,815 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-23 2026-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 26,574 15,033 130.26 613 127.04 0.3994
2026-01-23 2025-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 11,541 5,611 94.62 270 121.31 0.4231
2025-10-23 2025-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 5,930 4,650 363.28 122 293.55 0.3994
2025-07-22 2025-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 1,280 540 72.97 32 93.75 0.2397
2025-04-22 2025-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 740 483 187.94 17 220.00 0.1392
2025-01-23 2024-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 257 55 27.23 6 25.00 0.1035
2024-10-25 2024-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 202 202 4 0.1183
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.